ATE52920T1 - Zusammensetzung von alpha-alpha-vernetzten haemoglobin. - Google Patents

Zusammensetzung von alpha-alpha-vernetzten haemoglobin.

Info

Publication number
ATE52920T1
ATE52920T1 AT86301573T AT86301573T ATE52920T1 AT E52920 T1 ATE52920 T1 AT E52920T1 AT 86301573 T AT86301573 T AT 86301573T AT 86301573 T AT86301573 T AT 86301573T AT E52920 T1 ATE52920 T1 AT E52920T1
Authority
AT
Austria
Prior art keywords
alpha
composition
cross
linked
lys
Prior art date
Application number
AT86301573T
Other languages
English (en)
Inventor
Joseph Alan Walder
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of ATE52920T1 publication Critical patent/ATE52920T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT86301573T 1985-03-18 1986-03-06 Zusammensetzung von alpha-alpha-vernetzten haemoglobin. ATE52920T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/713,348 US4600531A (en) 1984-06-27 1985-03-18 Production of alpha-alpha cross-linked hemoglobins in high yield
EP86301573A EP0195558B1 (de) 1985-03-18 1986-03-06 Zusammensetzung von alpha-alpha-vernetzten Hämoglobinen

Publications (1)

Publication Number Publication Date
ATE52920T1 true ATE52920T1 (de) 1990-06-15

Family

ID=24865781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86301573T ATE52920T1 (de) 1985-03-18 1986-03-06 Zusammensetzung von alpha-alpha-vernetzten haemoglobin.

Country Status (6)

Country Link
US (1) US4600531A (de)
EP (1) EP0195558B1 (de)
JP (1) JP2707241B2 (de)
AT (1) ATE52920T1 (de)
CA (1) CA1273294A (de)
DE (1) DE3671374D1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
USRE34271E (en) * 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JP2962731B2 (ja) * 1986-11-10 1999-10-12 バイオピュアー、コーポレーション 超純枠半合成代用血液
US5189146A (en) * 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US5164272A (en) * 1987-12-03 1992-11-17 Chloride Silent Power Limited Alkali metal cell
CA1338244C (en) * 1988-08-17 1996-04-09 Xiang-Fu Wu Purification of hemoglobin and methemoglobin by bioselective elution
US5128452A (en) * 1989-04-19 1992-07-07 Baxter International Inc. Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate
US5844090A (en) * 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US6150506A (en) * 1989-05-10 2000-11-21 Baxter Biotech Technology Sarl Modified hemoglobin-like compounds and methods of purifying same
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
ES2204926T3 (es) 1989-05-10 2004-05-01 Baxter Biotech Technology S. .R.L. Procedimiento de preparacion de hemoglobina y derivados de hemoglobina a partir de manipulacion de bacterias y levaduras.
US6828125B1 (en) * 1989-05-10 2004-12-07 Baxter Biotech Technology, S.A.R.L. DNA encoding fused di-alpha globins and use thereof
US5439882A (en) * 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
ES2082971T3 (es) * 1990-03-14 1996-04-01 Univ Toronto Esteres de fosfato de acilo y modificacion de proteinas con los mismos.
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5352773A (en) * 1990-08-06 1994-10-04 Baxter International Inc. Stable hemoglobin based composition and method to store same
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
ATE119917T1 (de) * 1990-11-29 1995-04-15 Upjohn Co Mit imidoester quer-vernetzte hämoglobinzusammensetzungen.
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5334705A (en) * 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
EP0611306B1 (de) * 1991-11-08 1998-07-08 Somatogen, Inc. Hämoglobine als arzneimittelabgabesystem
US5334706A (en) * 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
US5900477A (en) * 1992-01-30 1999-05-04 Baxter International, Inc. Use of hemoglobin in the treatment of hemorrhagic shock
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
GB9617611D0 (en) * 1996-08-22 1996-10-02 Vasogen Inc Treatment of autoimmune disease
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5591457A (en) * 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5290919A (en) * 1992-08-28 1994-03-01 The University Of Maryland Baltimore Hemoglobin intramolecularly cross-linked with trivalent reagents
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6140071A (en) * 1994-01-27 2000-10-31 Somatogen, Inc. Proteins with mutations to decrease N-terminal methylation
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
US5895810A (en) * 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
JPH10501823A (ja) * 1995-04-10 1998-02-17 バクスター、インターナショナル、インコーポレイテッド クモ膜下出血の治療における架橋ヘモグロビンの使用
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
US6054427A (en) * 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US6180598B1 (en) 1999-10-07 2001-01-30 Deanna J. Nelson Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
US6670323B1 (en) 1999-11-12 2003-12-30 Baxter International, Inc. Reduced side-effect hemoglobin compositions
DE10031742A1 (de) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Verfahren zur Herstellung künstlicher Sauerstoffträger aus kovalent vernetzten Hämoglobinen mit verbesserten funktionellen Eigenschaften durch Vernetzung in Anwesenheit chemisch nicht reagierender Effektoren der Sauerstoffaffinität der Hämoglobine
DE10059720A1 (de) * 2000-11-30 2002-06-06 Roche Diagnostics Gmbh Verwendung intramolekular kovalent vernetzter Proteine als Bindepartner in Immunoassays
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1894573A3 (de) 2002-01-11 2013-06-12 Sangart, Inc. Verfahren und Zusammensetzungen für den Sauerstofftransport mit hoher Sauerstoffaffinität
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
EP1472280A4 (de) * 2002-01-11 2005-09-21 Sangart Inc Verfahren und zusammen setzungen zum sauerstofftransport, umfassend einen sauerstoffträger und ein kristalloid in einer hypertonen lösung
AU2003207503A1 (en) * 2002-01-11 2003-07-30 Sangart, Inc. Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
US7135554B1 (en) 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
ES2347805T3 (es) * 2004-08-31 2010-11-04 Sangart, Inc. Metodos para aumentar la estabilidad hemodinamica usando composiciones que transportan oxigeno.
EP2026824A2 (de) * 2006-05-09 2009-02-25 The United States Of America As Represented By the Sectretary of the Navy Multifunktionsblutersatz
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
WO2014179793A1 (en) 2013-05-03 2014-11-06 Washington University Blood substitute composition and method of use
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
DE2449885C3 (de) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4136093A (en) * 1976-04-23 1979-01-23 Biotest-Serum-Institut Gmbh Hemoglobin preparation with increased oxygen release
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376059A (en) * 1980-04-11 1983-03-08 Exxon Research And Engineering Co. Process for preparing artificial red cells
JPS5716815A (en) * 1980-07-02 1982-01-28 Ajinomoto Co Inc Oxygen transporting agent for artificial blood
US4401652A (en) * 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4473494A (en) * 1983-05-04 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Preparation of stroma-free, non-heme protein-free hemoglobin
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation

Also Published As

Publication number Publication date
EP0195558A3 (en) 1987-07-01
US4600531A (en) 1986-07-15
JP2707241B2 (ja) 1998-01-28
EP0195558B1 (de) 1990-05-23
DE3671374D1 (de) 1990-06-28
EP0195558A2 (de) 1986-09-24
JPS61215329A (ja) 1986-09-25
CA1273294A (en) 1990-08-28

Similar Documents

Publication Publication Date Title
ATE52920T1 (de) Zusammensetzung von alpha-alpha-vernetzten haemoglobin.
PT83761B (pt) Metodo para a producao de interleuquina-4 de mamifero
ATE57836T1 (de) Nichtdenaturierte virusfreie biologisch aktive proteinderivate.
FI101381B1 (fi) Nukleotidisekvenssi ja menetelmä polypeptidin HSA(1-387) tuottamiseksi
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ATE59962T1 (de) Thrombin bindender stoff und verfahren zu seiner herstellung.
ES2070116T3 (es) Peptidos que inhiben la union del factor von willebrand.
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
DK440985D0 (da) Enzymatisk proces
ATE71658T1 (de) Verfahren zur herstellung von humanlysozym.
ES8503238A1 (es) Procedimiento de preparar concentrados y nutrimentos proteinicos
ATE105480T1 (de) Thrombin bindende substanz und verfahren zu ihrer herstellung.
GR3017198T3 (en) Process for modification of a molecular sieve.
EP0576038A3 (en) Method for measuring tissue plasminogen activator, antithrombin iii and soluble fibrin
ES2065318T3 (es) Sustancia que se une a trombina y procedimiento para su preparacion.
DE3650477D1 (de) Produktion von Cystinreste enthaltenden aktiven Proteinen
ES2033295T3 (es) Un metodo para preparar un activador de plasminogeno.
DE3582504D1 (de) Waermedefibrinogenierung eines ahf-praeparates.
ATE115188T1 (de) Antikörper gegen fibrin, immunogen zur herstellung desselben, verfahren zur bestimmung von fibrin und pharmazeutisches präparat auf basis der antikörper.
DE3854195D1 (de) Polypeptid-verbindungen.
NO161274C (no) Fremgangsm te for fremstilling av immuninterferon.
DE3586537D1 (de) Verfahren zur herstellung von 2-nitro-3-aminopyridin sowie der dabei als zwischenprodukt auftretende n,n'-di-(2-nitro-3-pyridyl)harnstoff.
IS3438A7 (is) Hliðstæð aðferð við tengingu fjölliða stórsameindar við CSF-1 þáttinn (prótein sem örvar skiptingu átfruma)
IT8440033A1 (it) Procedimento perfezionato per la produzione di suole per cingoli e suole così realizzate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time